tetano
Editor, Senior Moderator
Int J Mol Sci. 2018 May 8;19(5). pii: E1400. doi: 10.3390/ijms19051400.
[h=1]The Annexin A1 Receptor FPR2 Regulates the Endosomal Export of Influenza Virus.[/h] Rahman F[SUP]1[/SUP], Chebbo M[SUP]2[/SUP], Courtin N[SUP]3[/SUP], Fotso Fotso A[SUP]4[/SUP], Alessi MC[SUP]5[/SUP], Riteau B[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The Formyl Peptide Receptor 2 (FPR2) is a novel promising target for the treatment of influenza. During viral infection, FPR2 is activated by annexinA1, which is present in the envelope of influenza viruses; this activation promotes virus replication. Here, we investigated whether blockage of FPR2 would affect the genome trafficking of influenza virus. We found that, upon infection and cell treatment with the specific FPR2 antagonist WRW4 or the anti-FPR2 monoclonal antibody, FN-1D6-AI, influenza viruses were blocked into endosomes. This effect was independent on the strain and was observed for H1N1 and H3N2 viruses. In addition, blocking FPR2signaling in alveolar lung A549 epithelial cells with the monoclonal anti-FPR2 antibody significantly inhibited virus replication. Altogether, these results show that FPR2signaling interferes with the endosomal trafficking of influenza viruses and provides, for the first time, the proof of concept that monoclonal antibodies directed against FPR2 inhibit virus replication. Antibodies-based therapeutics have emerged as attractive reagents in infectious diseases. Thus, this study suggests that the use of anti-FPR2 antibodies against influenza hold great promise for the future.
[h=4]KEYWORDS:[/h] Annexin A1; FPR2; influenza
PMID: 29738458 DOI: 10.3390/ijms19051400
Free full text
[h=1]The Annexin A1 Receptor FPR2 Regulates the Endosomal Export of Influenza Virus.[/h] Rahman F[SUP]1[/SUP], Chebbo M[SUP]2[/SUP], Courtin N[SUP]3[/SUP], Fotso Fotso A[SUP]4[/SUP], Alessi MC[SUP]5[/SUP], Riteau B[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The Formyl Peptide Receptor 2 (FPR2) is a novel promising target for the treatment of influenza. During viral infection, FPR2 is activated by annexinA1, which is present in the envelope of influenza viruses; this activation promotes virus replication. Here, we investigated whether blockage of FPR2 would affect the genome trafficking of influenza virus. We found that, upon infection and cell treatment with the specific FPR2 antagonist WRW4 or the anti-FPR2 monoclonal antibody, FN-1D6-AI, influenza viruses were blocked into endosomes. This effect was independent on the strain and was observed for H1N1 and H3N2 viruses. In addition, blocking FPR2signaling in alveolar lung A549 epithelial cells with the monoclonal anti-FPR2 antibody significantly inhibited virus replication. Altogether, these results show that FPR2signaling interferes with the endosomal trafficking of influenza viruses and provides, for the first time, the proof of concept that monoclonal antibodies directed against FPR2 inhibit virus replication. Antibodies-based therapeutics have emerged as attractive reagents in infectious diseases. Thus, this study suggests that the use of anti-FPR2 antibodies against influenza hold great promise for the future.
[h=4]KEYWORDS:[/h] Annexin A1; FPR2; influenza
PMID: 29738458 DOI: 10.3390/ijms19051400
Free full text